Regulation of EP4 expression via the Sp-1 transcription factor: Inhibition of expression by anti-cancer agents

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1783, Issue 6, 2008, Pages 1211-1219

  Kambe, Atsushi ^a,b   Iguchi, Genzo ^a   Moon, Yuseok ^c   Kamitani, Hideki ^b   Watanabe, Takashi ^b   Eling, Thomas E ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b TOTTORI UNIVERSITY   (Japan)

^c Pusan National University School of Medicine   (South Korea)

Author keywords

Erks activation; Glioblastoma; PPAR; Prostaglandin EP4 receptor; Sp 1 phosphorylation

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANTINEOPLASTIC AGENT; CIGLITAZONE; DNA; INDOMETACIN; MITOGEN ACTIVATED PROTEIN KINASE; NETOGLITAZONE; PIOGLITAZONE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROSIGLITAZONE; SULINDAC SULFIDE; TRANSCRIPTION FACTOR SP1; TROGLITAZONE;

ARTICLE; BINDING SITE; CANCER CELL; CELL GROWTH; CONTROLLED STUDY; DNA BINDING; EP4 GENE; GENE; GENE EXPRESSION; GENE REPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MUTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TRANSCRIPTION INITIATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BLOTTING, WESTERN; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CHROMANS; CHROMATIN IMMUNOPRECIPITATION; COLONY-FORMING UNITS ASSAY; CYCLOOXYGENASE 2 INHIBITORS; DNA PRIMERS; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IMMUNOPRECIPITATION; LUCIFERASES; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); RECEPTORS, PROSTAGLANDIN E; RNA, MESSENGER; RNA, SMALL INTERFERING; SP1 TRANSCRIPTION FACTOR; THIAZOLIDINEDIONES; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 43549097540     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2008.01.032     Document Type: Article

References (41)

1. Henson J.W. Treatment of glioblastoma multiforme: a new standard. Arch. Neurol. 63 (2006) 337-341
2. Sheehan K.M., Sheahan K., O'Donoghue D.P., MacSweeney F., Conroy R.M., Fitzgerald D.J., and Murray F.E. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282 (1999) 1254-1257
3. Ristimäki A., Sivula A., Lundin J., Lundin M., Salminen T., Haglund C., Joensuu H., and Isola F. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 62 (2002) 632-635
4. Erkinheimo T.L., Lassus H., Finne P., van Rees B.P., Leminen A., Ylikorkala O., Haglund C., Butzow R., and Ristimäki A. Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma. Clin. Cancer Res. 10 5 (2004) 38-545
5. Tucker O.N., Dannenberg A.J., Yang E.K., Zhang F., Teng L., Daly J.M., Soslow R.A., Masferrer J.L., Woerner B.M., Koki A.T., and Fahey 3rd T.J. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 59 (1999) 987-990
6. Fujino H., West K.A., and Regan J.W. Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. J. Biol. Chem. 277 (2002) 2614-2619
7. Sonoshita M., Takaku K., Sasaki N., Sugimoto Y., Ushikubi F., Narumiya S., Oshima M., and Taketo M.M. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat. Med. 7 (2001) 1048-1051
8. Chang S.H., Ai Y., Breyer R.M., Lane T.F., and Hla T. The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia. Cancer Res. 65 (2005) 4496-4499
9. Chang S.H., Liu C.H., Conway R., Han D.K., Nithipatikom K., Trifan O.C., Lane T.F., and Hla T. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 591-596
10. Fiebich B.L., Schleicher S., Spleiss O., Czygan M., and Hull M. Mechanisms of prostaglandin E2-induced interleukin-6 release in astrocytes: possible involvement of EP4-like receptors, p38 mitogen-activated protein kinase and protein kinase C. J. Neurochem. 79 (2001) 950-958
11. Raza S.M., Fuller G.N., Rhee C.H., Huang S., Hess K., Zhang W., and Sawaya R. Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis. Clin. Cancer Res. 10 (2004) 212-221
12. Shono T., Tofilon P.J., Bruner J.M., Owolabi O., and Lang F.F. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 61 (2001) 4375-4381
13. Han S., and Roman J. Suppression of prostaglandin E2 receptor subtype EP2 by PPARgamma ligands inhibits human lung carcinoma cell growth. Biochem. Biophys. Res. Commun. 314 (2004) 1093-1099
14. Han S., Ritzenthaler J.D., Wingerd B., and Roman J. Activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) increases the expression of prostaglandin E2 receptor subtype EP4. The roles of phosphatidylinositol 3-kinase and CCAAT/enhancer-binding protein beta. J. Biol. Chem. 280 (2005) 33240-33249
15. Bottone Jr. F.G., Martinez J.M., Alston-Mills B., and Eling T.E. Gene modulation by Cox-1 and Cox-2 specific inhibitors in human colorectal carcinoma cancer cells. Carcinogenesis 25 (2004) 349-357
16. Baek S.J., and Eling T.E. Changes in gene expression contributes to cancer prevention by COX inhibitors. Prog. Lipid Res. 45 (2006) 1-16
17. Lee S.H., Yamaguchi K., Kim J.S., Eling T.E., Safe S., Park Y., and Baek S.J. Conjugated linoleic acid stimulates an anti-tumorigenic protein NAG-1 in an isomer specific manner. Carcinogenesis 27 (2006) 972-981
18. Kim J.S., Baek S.J., Sali T., and Eling T.E. The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15. Mol. Cancer Ther. 4 (2005) 487-493
19. Baek S.J., Kim J.S., Moore S.M., Lee S.H., Martinez J.M., and Eling T.E. Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol. Pharmacol. 67 (2005) 356-364
20. Baek S.J., Kim J.S., Nixon J.B., DiAugustine R.P., and Eling T.E. Expression of NAG-1, a transforming growth factor-beta superfamily member, by troglitazone requires the early growth response gene EGR-1. J. Biol. Chem. 279 (2004) 6883-6892
21. Foord S.M., Marks B., Stolz M., Bufflier E., Fraser N.J., and Lee M.G. The structure of the prostaglandin EP4 receptor gene and related pseudogenes. Genomics 35 (1996) 182-188
22. Baek S.J., Horowitz J.M., and Eling T.E. Molecular cloning and characterization of human nonsteroidal anti-inflammatory drug-activated gene promoter. Basal transcription is mediated by Sp1 and Sp3. J. Biol. Chem. 276 (2001) 33384-33392
23. Bonello M.R., and Khachigian L.M. Fibroblast growth factor-2 represses platelet-derived growth factor receptor-alpha (PDGFR-alpha) transcription via ERK1/2-dependent Sp1 phosphorylation and an atypical cis-acting element in the proximal PDGFR-alpha promoter. J. Biol. Chem. 279 (2004) 2377-2382
24. Taniura S., Kamitani H., Watanabe T., and Eling T.E. Transcriptional regulation of Cycloocygenase-1 by histone deacetylase inhibitors in normal astrocyte cells. J. Biol. Chem. 277 (2002) 16823-16830
25. Fujino H., Xu W., and Regan J.W. Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J. Biol. Chem. 278 (2003) 12151-12156
26. Amin R., Kamitani H., Sultana H., Taniura S., Islam A., Sho A., Ishibashi M., Eling T.E., and Watanabe T. Aspirin and indomethacin exhibit antiproliferative effects and induce apoptosis in T98G human glioblastoma cells. Neurol. Res. 25 (2003) 370-376
27. Motomura W., Tanno S., Takahashi N., Nagamine M., Fukuda M., Kohgo Y., and Okumura T. Involvement of MEK-ERK signaling pathway in the inhibition of cell growth by troglitazone in human pancreatic cancer cells. Biochem. Biophys. Res. Commun. 332 (2005) 89-94
28. Yin F., Bruemmer D., Blaschke F., Hsueh W.A., Law R.E., and Herle A.J. Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells. Oncogene 23 (2004) 4614-4623
29. Baek S.J., Wilson L.C., Hsi L.C., and Eling T.E. Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity. J. Biol. Chem. 278 (2003) 5845-5853
30. Milanini-Mongiat J., Pouyssegur J., and Pages G. Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J. Biol. Chem. 277 (2002) 20631-20639
31. Mutoh M., Watanabe K., Kitamura T., Shoji Y., Takahashi M., Kawamori T., Tani K., Kobayashi M., Maruyama T., Kobayashi K., Ohuchida S., Sugimoto Y., Narumiya S., Sugimura T., and Wakabayashi K. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res. 62 (2002) 28-32
32. Chell S.D., Witherden I.R., Dobson R.R., Moorghen M., Herman A.A., Qualtrough D., Williams A.C., and Paraskeva C. Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Res. 66 (2006) 3106-3113
33. Castellone M.D., Teramoto H., Williams B.O., Druey K.M., and Gutkind J.S. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310 (2005) 1504-1510
34. Wang D., Buchanan F.G., Wang H., Dey S.K., and DuBois R.N. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. Cancer Res. 65 (2005) 1822-1829
35. Chien E.K., and MacGregor C. Expression and regulation of the rat prostaglandin E2 receptor type 4 (EP4) in pregnant cervical tissue. Am. J. Obstet. Gynecol. 189 (2003) 1501-1510
36. Sugawara A., Uruno A., Kudo M., Ikeda Y., Sato K., Taniyama Y., Ito S., and Takeuchi K. Transcription suppression of thromboxane receptor gene by peroxisome proliferator-activated receptor-gamma via an interaction with Sp1 in vascular smooth muscle cells. J. Biol. Chem. 277 (2002) 9676-9683
37. Chu S., and Ferro T.J. Sp1: regulation of gene expression by phosphorylation. Gene 348 (2005) 1-11
38. Fischer C., Sanchez-Ruderisch H., Welzel M., Wiedenmann B., Sakai T., André S., Gabius H.J., Khachigian L., Detjen K.M., and Rosewicz S. Galectin-1 interacts with the {alpha}5{beta}1 fibronectin receptor to restrict carcinoma cell growth via induction of p21 and p27. J. Biol. Chem. 280 (2005) 37266-37277
39. Karlseder J., Rotheneder H., and Wintersberger E. Interaction of Sp1 with the growth- and cell cycle-regulated transcription factor E2F. Mol. Cell. Biol. 16 (1996) 1659-1667
40. Baek S.J., Okazaki R., Lee S.H., Martinez J., Kim J.S., Yamaguchi K., Mishina Y., Martin D.W., Shoieb A., McEntee M.F., and Eling T.E. Nonsteroidal anti-inflammatory drug activated gene-1 overexpression in transgenic mice suppresses intestinal neoplasia. Gastroenterology 131 (2006) 1553-1560
41. Bae M.A., and Song B.J. Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells. Mol. Pharmacol. 63 (2003) 401-408